Previous 10 | Next 10 |
Matthew Davis, chief medical officer of biotechnology company Tiziana Life Sciences ( NASDAQ: TLSA ), has purchased 75,000 shares of the company's common stock at $0.83 per share. The transaction increases Davis' total holding in the firm to 175,000 common shares. Earl...
Tiziana Life Sciences' ( NASDAQ: TLSA ) Chairman Gabriele Cerrone has indirectly purchased 20,145 common shares of the company priced at $0.66 each through Panetta Partners. The acquisition takes Cerrone's interests from 37.72% to 37.74%. For further detail...
The second Expanded Access patient (EA2) demonstrated improved walking as measured by gait stability and endurance The patient showed clinically significant improvement in the Expanded Disability Status Scale (EDSS). The 6-month PET imaging will occur in Q4 2022 to confi...
Tiziana Life Sciences ( NASDAQ: TLSA ) has announced a share purchase by its executive chairman, Gabriele Cerrone. Panetta Partners, an entity in which Cerrone has a beneficial interest, purchased 29,318 common shares priced between $0.78 and $0.81 per share. The acqui...
NEW YORK, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd.(Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announces that a Lawrence &...
NEW YORK, Sept. 09, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd.(Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today announces that it has been notified that Mat...
Tiziana Life Sciences ( NASDAQ: TLSA ) said that its Executive Chairman Gabriele Cerrone bought additional common shares, raising stake in the company to 37.70% from 37.61%. The company added that Panetta Partners, an entity in which Cerrone ha...
Tiziana Life Sciences ( NASDAQ: TLSA ) has announced a purchase of 20K common shares by Panetta Partners, an entity in which executive chairman Gabriele Cerrone holds a beneficial interest. The shares were acquired at $0.75 each. The transaction brings Mr Cerrone's interes...
NEW YORK, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd.(Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel drug delivery approaches, today announced the presentation of a...
Tiziana Life Sciences ( NASDAQ: TLSA ) said it appointed Matthew Davis as chief medical officer and acting chief scientific officer, effective immediately. Last week, Kunwar Shailubhai had resigned as CEO, chief scientific officer and director, effective ...
News, Short Squeeze, Breakout and More Instantly...
Tiziana Life Sciences plc Company Name:
TLSA Stock Symbol:
NASDAQ Market:
Shares of Tesla, Inc. (NASDAQ:TSLA) rose sharply in today's pre-market trading following first-quarter results. Tesla posted weaker-than-expec...
Pegasystems Inc. (PEGA) is expected to report $0.2 for Q1 2024 Masco Corporation (MAS) is expected to report $0.87 for Q1 2024 Avery Dennison Corporation (AVY) is expected to report $2.15 for Q1 2024 Vista Energy S.A.B. de C.V. American Depositary Shares each representing one series A...
Tiziana Life Sciences Ltd (TLSA) is expected to report for Q4 2023